Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombivax HB immune response in chronic HCV
NCT02429583Phase 4Terminated
- Sponsor
- The Rockefeller University
- Start
- May 2015
- Primary completion
- Nov 2018
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of Hepatitis B vaccine in hepatitis B (HBV), sponsored by The Rockefeller University. Started May 2015; status: terminated.
02
Drugs
Hepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT02429583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02429583.